Aerovate Therapeutics Announces Leadership Changes
Ticker: JBIO · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1798749
Sentiment: neutral
Topics: leadership-change, board-of-directors, personnel
TL;DR
Aerovate's CMO is out, two new directors in. Big board shakeup.
AI Summary
Aerovate Therapeutics, Inc. announced on October 6, 2024, the departure of its Chief Medical Officer, Dr. Lisa Rojkowska. The company also reported the election of two new directors, Dr. Jonathan Leff and Mr. David Epstein, to its Board. These changes are effective immediately.
Why It Matters
Changes in key leadership and board composition can signal shifts in company strategy or operational focus, potentially impacting future drug development and market performance.
Risk Assessment
Risk Level: medium — Leadership changes and board restructuring can introduce uncertainty regarding the company's strategic direction and execution capabilities.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- Dr. Lisa Rojkowska (person) — Departing Chief Medical Officer
- Dr. Jonathan Leff (person) — Newly Elected Director
- Mr. David Epstein (person) — Newly Elected Director
- October 6, 2024 (date) — Effective date of changes
FAQ
Who has departed from Aerovate Therapeutics?
Dr. Lisa Rojkowska, the Chief Medical Officer, has departed from Aerovate Therapeutics.
When were the changes effective?
The changes were effective as of October 6, 2024.
Who were the new directors elected to the board?
Dr. Jonathan Leff and Mr. David Epstein were elected as new directors.
What is Aerovate Therapeutics' principal executive office address?
Aerovate Therapeutics' principal executive office is located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.
What is the Commission File Number for Aerovate Therapeutics?
The Commission File Number for Aerovate Therapeutics is 001-40544.
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-10 17:04:52
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share AVTE The Nasdaq
Filing Documents
- tmb-20241006x8k.htm (8-K) — 41KB
- 0001798749-24-000052.txt ( ) — 162KB
- tmb-20241006.xsd (EX-101.SCH) — 3KB
- tmb-20241006_lab.xml (EX-101.LAB) — 16KB
- tmb-20241006_pre.xml (EX-101.PRE) — 11KB
- tmb-20241006x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aerovate Therapeutics, Inc. Date: October 10, 2024 By: /s/ George A. Eldridge George A. Eldridge Chief Financial Officer